At Intarcia, through the passion and commitment of our employees, we seek to leverage our technologies in drug development and delivery to provide improved therapeutic outcomes for patients and to help patients achieve a better quality of life.

One of the biggest problems in chronic diseases is millions of patients lack effective control of their condition due to sub-optimal effectiveness of their medication, and the fact is, the majority of patients with chronic conditions stop taking these pills and injections, after just three-to-six months. We are aiming to address these serious and costly unmet needs by introducing a new way to deliver once-yearly therapies that hold the potential for game-changing improvements in outcomes and patient adherence over time.

Delivering medicines for up to a year and beyond has the potential to ensure improved patient adherence and compliance. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins, peptides, antibody fragments, and other high-potency small molecules at or above body temperature, and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform, the Medici Drug Delivery System. Intarcia continues to conduct research and development, utilizing its platform technology, to treat other chronic, serious disorders such as diabetes, obesity, autoimmune, and other serious diseases.

Developing Products with Significant Market Potential

Intarcia strives to develop product candidates with a demonstrated potential to deliver significant therapeutic improvements over existing therapies. We focus on therapies that address significant unmet medical needs and represent large commercial opportunities. The therapies we are developing:

  • Are based on promising therapeutic classes with proven clinical safety and activity;
  • Hold potential to represent significant improvements over the established standards of care;
  • May qualify for accelerated development and regulatory pathways; and
  • Create proprietary product candidates, securing or extending exclusivity.

By targeting product candidates from proven therapeutic classes and existing safety and clinical data, our development approach allows us to mitigate risks while reducing the cost and time required for developing products. If we are able to complete product development with fewer clinical trials than are required for a new therapeutic, we may have lower development costs and shorter timelines. By delivering these product candidates facilitated by Intarcia's Medici Drug Delivery System, we strive to deliver therapy with a truly optimized therapeutic index.

Maximizing Commercial Potential of The Medici Drug Delivery System


Based on the successful completion of Phase 3 clinical trials for ITCA 650, Intarcia’s investigational therapy in type 2 diabetes, we continue to evaluate new opportunities for novel and proprietary product candidates, with efforts focused around two areas:

  • Evaluation of new applications of the Medici Drug Delivery System to develop products for which we can hold exclusive development and commercialization rights; and
  • Exploration of collaborative opportunities with partners to which our formulation and drug delivery technology and expertise can lend enhancement of life-cycle management, product line extension or a competitive edge.

To discuss opportunities, please contact our business development and licensing office at busdev@intarcia.com.

Our Vision

Unleashing talent to deliver disruptively innovative and life-changing medicines that transform business models, standards of care, and outcomes for patients, payers and providers.

Pipeline News

Intarcia Acquires Phoundry Pharmaceuticals
Acquisition of world class peptide team and library of optimized peptide assets creates opportunity for "NextGen" ITCA 650 combo therapy targeting diabetes and obesity. Other important diseases to be explored for mid and long-term pipeline.

Intarcia and Numab Sign Multi-Asset Collaboration to Develop Once-Yearly Therapies
Collaboration combines Intarcia’s proprietary delivery technologies with Numab’s novel multi-specific antibody technology.